Britannia Life Sciences Inc

As of June 30, 2026, Britannia Life Sciences Inc carries a market capitalization of 12.34M, placing it among publicly traded companies globally. Its enterprise value stands at 141,674.43, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Britannia Life Sciences Inc has 164.59M shares outstanding.

As of June 30, 2026, Britannia Life Sciences Inc trades at a trailing price-to-earnings ratio of 0.74. The price-to-sales ratio is 29.98, and the price-to-book ratio stands at 0.56.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 141,674.43 versus a market cap of 12.34M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Britannia Life Sciences Inc maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.96, indicating moderate leverage, while an interest coverage ratio of -65.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Britannia Life Sciences Inc posted a return on equity (ROE) of 119.87, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -9.53, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 95.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 111.78, useful for judging operating efficiency across full business cycles.

Over the twelve months ended June 30, 2026, Britannia Life Sciences Inc recorded 507,837.00 in income tax expense. That works out to an effective tax rate of 3.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 15.47M, leaving 16.54M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Britannia Life Sciences Inc's stock has declined approximately 26.32% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.08.

Over the twelve months ended June 30, 2026, Britannia Life Sciences Inc generated 406,436.00 in revenue and converted that into 16.54M in net income, yielding earnings per share of 0.09. EBITDA reached -1.41M, while operating income came in at -1.42M.

As of June 30, 2026, Britannia Life Sciences Inc holds 12.41M in cash and equivalents against 211,517.00 in total debt, resulting in a net debt position of -11.72M. Total book value stands at 22.05M, with working capital of 11.93M providing operational flexibility.

Britannia Life Sciences Inc produced -389,947.00 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Britannia Life Sciences Inc posted a gross margin of 22.83, reflecting its pricing power and cost economics. The operating margin of -348.35 and net profit margin of 4,069.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.28, meaning Britannia Life Sciences Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Britannia Life Sciences Inc's most recent stock split took place on November 18, 2021 with a 10:1 split ratio.

As of June 30, 2026, Britannia Life Sciences Inc has an Altman Z-Score of 3.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.